Paclitaxel: A pharmacoeconomic review of its use in the treatment of ovarian cancer

PharmacoEconomics

Volumn 19, Issue 12, 2001, Pages 1227-1259

  Young, Melissa ^a   Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; DRUG COST; DRUG USE; HUMAN; OVARY CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

EID: 0035689892     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200119120-00005     Document Type: Review

References (58)

1. Paclitaxel: An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancer
2. Chemotherapy for ovarian cancer - A consensus statement on standard practice
3. Advanced epithelial ovarian cancer: 1998 consensus statements
4. Paclitaxel: A pharmacoeconomic review of its use in non-small cell lung cancer
5. Pharmacoeconomic considerations in treating ovarian cancer
6. Cost, quality of life and outcome measures in ovarian cancer
7. Treating advanced ovarian cancer within the health maintenance organization: A Kaiser permanente approach
8. Palliative therapy in advanced ovarian cancer: Balancing patient expectations, quality of life and cost
9. Trends in United States ovarian cancer mortality, 1979-1995
10. Cancer statistics 2000
11. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
12. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results
13. The effect of reimbursement policies on the management of Medicare patients with refractory ovarian cancer
14. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens
15. Resource implications of palliative chemotherapy for ovarian cancer
16. Implementation of disease management guidelines in patients with advanced ovarian cancer
17. Oxaliplatin: A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies
18. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer gynecology group
19. Second-line therapy of ovarian carcinoma
20. Pilot study of the paclitaxel, oxaliplatin and cisplatin combination in patients with advanced/recurrent ovarian cancer
21. First-line treatment of advanced, suboptimally debulked, epithelial ovarian cancer (EOC) with the combination of ifosfamide, paclitaxel and cisplatin (ITP): Long-term results of a phase II study
22. Paclitaxel, cisplatin and Ionidamine in advanced ovarian cancer: A phase III study
23. Paclitaxel, cisplatin, and epirubicin first-line chemotherapy in stage III and IV ovarian carcinoma: Long term results of a phase II study
24. Estimating the costs attributable to a disease with application to ovarian cancer
25. Economic analysis of carboplatin versus cisplatin in lung and ovarian cancer
26. Is paclitaxel cost-effective as first-line therapy in advanced ovarian cancer? A medico-economic model
27. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes and costs in women receiving chemotherapy for advanced ovarian cancer
28. Depression, anxiety, and quality of life in patients with epithelial ovarian cancer
29. Quality of life in ovarian cancer patients receiving chemotherapy
30. Quality of life issues in the management of ovarian cancer
31. Chemotherapy for ovarian cancer
32. Chemotherapy for ovarian cancer
33. Chemotherapy for ovarian cancer
34. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group Study
35. Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer: Update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Trial
36. Exploratory phase III study of placlitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer
37. Randomized phase III study of cisplatin/paclitaxel (PAC) versus carboplatin/PAC in optimal stage III epithelial ovarian cancer: A Gynecologic Oncology Group Trial (GOG 158)
38. First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer- a new standard of care?
39. Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy
40. Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the gynecologic oncology group
41. Three cycles versus six cycles of adjuvant paclitaxel (Taxol)/carboplatin in early stage ovarian cancer
42. Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma: A lifetime cost-effectiveness analysis
43. Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer
44. Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: An Ontario perspective
45. Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer: A European perspective
46. Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer
47. Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma: A lifetime cost-effectiveness analysis
48. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance
49. Cost analysis of second-line therapies for platinum-refractory ovarian cancer: Reimbursement dilemmas for Medicare patients
50. Comparative cost-effectiveness of paclitaxel-cisplatin vs cyclophosphamide-cisplatin in women with advanced epithelial ovarian cancer: Results from a randomized trial
51. Cost effectiveness of paclitaxel/cisplatin compared to cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium
52. Cost-effectiveness analysis of paclitaxel in first-line chemotherapy of advanced ovarian cancer
53. Comparing cost-effectiveness analyses for the clinical oncology setting: The example of the Gynecologic Oncology Group 111 Trial
54. Pharmacoeconomic profile of taxanes in advanced ovarian cancer